Clinical Trial Update: Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating personalized risk-adapted therapy in post-pubertal patients with newly diagnosed medulloblastoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medulloblastoma

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Medulloblastoma | Phase 2 | Status: TERMINATED